Clinical trial • Phase I • Oncology
Clinical trial in Polymetastatic solid cancers
Phase I trial for Polymetastatic solid cancers. 20 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Polymetastatic solid cancers
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 09-01-2025
- First CTIS Authorization Date
- 24-01-2025
Trial design
Phase I trial across 1 site in France.
- Target Sample Size
- 20
- Trial Duration For Participant
- 3653
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 120
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
France
- Earliest CTIS Part Ii Submission Date
- 23-01-2025
- Latest Decision Or Authorization Date
- 24-01-2025
- Processing Time Days
- 1
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Commissariat a l'Energie Atomique et aux Energies Alternatives
- Department Name
- Service Hospitalier Frederic Joliot
- Contact Person Name
- Vincent LEBON
- Contact Person Email
- Vincent.LEBON@cea.fr
Sponsor
Primary sponsor
- Full Name
- Commissariat a l'Energie Atomique et aux Energies Alternatives
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- France
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)